Dianthus Therapeutics Inc. (DNTH)vsRevolution Medicines Inc (RVMD)
DNTH
Dianthus Therapeutics Inc.
$92.48
+3.56%
HEALTHCARE · Cap: $5.03B
RVMD
Revolution Medicines Inc
$176.35
-2.41%
HEALTHCARE · Cap: $41.76B
Smart Verdict
WallStSmart Research — data-driven comparison
Revolution Medicines Inc generates 7169% more annual revenue ($197.56M vs $2.72M). RVMD leads profitability with a 0.0% profit margin vs 0.0%. DNTH earns a higher WallStSmart Score of 34/100 (F).
DNTH
Avoid34
out of 100
Grade: F
RVMD
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-67.0%
Fair Value
$29.90
Current Price
$92.48
$62.58 premium
Margin of Safety
+89.8%
Fair Value
$1883.88
Current Price
$176.35
$1707.53 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 205.6% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
ROE of -22.7% — below average capital efficiency
Trading at 15.9x book value
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : DNTH
The strongest argument for DNTH centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 205.6% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : DNTH
The primary concerns for DNTH are EPS Growth, Profit Margin, Piotroski F-Score.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
DNTH profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.
RVMD carries more volatility with a beta of 1.43 — expect wider price swings.
DNTH is growing revenue faster at 205.6% — sustainability is the question.
DNTH generates stronger free cash flow (-51M), providing more financial flexibility.
Bottom Line
DNTH scores higher overall (34/100 vs 23/100) and 205.6% revenue growth. RVMD offers better value entry with a 89.8% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Dianthus Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. The company is headquartered in New York, New York.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?